Quanterix Corporation

Quanterix is a life sciences company that has developed digital immunoassay platforms. The company's platforms are based on its proprietary digital Simoa detection technology. The company's Simoa bead-based and planar array platforms enable customers to detect protein biomarkers in low concentrations in blood, serum and other fluids that, in a number of cases, are undetectable using analog immunoassay technologies, and also allow researchers to define and validate the function of protein biomarkers that are only present in low concentrations. The company is focusing on protein detection. In addition, the company is developing its Simoa bead-based technology to detect nucleic acids in biological samples.
  • TickerQTRX
  • ISINUS74766Q1013
  • ExchangeNASDAQ Stock Market
  • SectorHealth Care Equipment & Services
  • CountryUnited States
QTRX Quanterix Corpo... (Health Care)

Quanterix Corp: 1 director

A director at Quanterix Corp sold after exercising options/sold 16,661 shares at 55.469USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listi...

 PRESS RELEASE
QTRX Quanterix Corpo... (Health Care)

Quanterix’ Simoa Technology Powers Largest and Most Diverse Global Inv...

BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its has been used in a worldwide collaborative study of the plasma neurofilament light (NfL) biomarker to evaluate its utility for a range of neurological conditions. Published in , the research marks the most robust effort to date assessing the use of NfL in blood to screen for neurodegeneration as a cause of cognitive symptoms; differentiate among neurodegenerative disorders and distinguish psychiatric disorders; and de...

 PRESS RELEASE
QTRX Quanterix Corpo... (Health Care)

Quanterix Chairman and CEO Kevin Hrusovsky to Present at the Goldman S...

BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that Chairman and Chief Executive Officer, Quanterix, Kevin Hrusovsky will be delivering a virtual presentation at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10th at 3:50pm ET. Attendees can access the public webcast at or by visiting the News & Events page within the Investors section of the Quanterix website at . Replays of the webcast will be available on the Quanterix website for 90 days following the conference. ...

 PRESS RELEASE
QTRX Quanterix Corpo... (Health Care)

Quanterix Appoints Masoud Toloue as President of Quanterix and Diagnos...

BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ: QTRX), a company helping to transform healthcare with digital protein biomarker technology enabling precision health, today announced it has named Masoud Toloue to the position of President of Quanterix and Diagnostics, effective June 9, 2021. “We are excited to welcome Masoud to our team at such an important moment for Quanterix,” said Kevin Hrusovsky, Chairman and Chief Executive Officer Quanterix. “We are making important strides in advancing our diagnostic capability and assays, given the NIH RADx funding, our COVID-19 Emergency Use Authorizat...

 PRESS RELEASE
QTRX Quanterix Corpo... (Health Care)

Quanterix Corporation Releases Operating Results for First Quarter 202...

BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ: QTRX), a company helping to transform healthcare with digital protein biomarker technology enabling precision health, today announced financial results for the three months ending March 31, 2021. “We made productive advances on our strategic and operational priorities during the first quarter 2021,” said Chairman, Chief Executive Officer and President, Quanterix, Kevin Hrusovsky. “The precision health ecosystem continues to catalyze interest and adoption from healthcare payors, government agencies, academia, and pharmaceutical companies as they ma...

QTRX Quanterix Corpo... (Health Care)

Quanterix Corp: 1 director

A director at Quanterix Corp sold after exercising options/sold 16,661 shares at 55.469USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listi...

 PRESS RELEASE
QTRX Quanterix Corpo... (Health Care)

Quanterix’ Simoa Technology Powers Largest and Most Diverse Global Inv...

BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its has been used in a worldwide collaborative study of the plasma neurofilament light (NfL) biomarker to evaluate its utility for a range of neurological conditions. Published in , the research marks the most robust effort to date assessing the use of NfL in blood to screen for neurodegeneration as a cause of cognitive symptoms; differentiate among neurodegenerative disorders and distinguish psychiatric disorders; and de...

 PRESS RELEASE
QTRX Quanterix Corpo... (Health Care)

Quanterix Chairman and CEO Kevin Hrusovsky to Present at the Goldman S...

BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that Chairman and Chief Executive Officer, Quanterix, Kevin Hrusovsky will be delivering a virtual presentation at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10th at 3:50pm ET. Attendees can access the public webcast at or by visiting the News & Events page within the Investors section of the Quanterix website at . Replays of the webcast will be available on the Quanterix website for 90 days following the conference. ...

 PRESS RELEASE
QTRX Quanterix Corpo... (Health Care)

Quanterix Appoints Masoud Toloue as President of Quanterix and Diagnos...

BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ: QTRX), a company helping to transform healthcare with digital protein biomarker technology enabling precision health, today announced it has named Masoud Toloue to the position of President of Quanterix and Diagnostics, effective June 9, 2021. “We are excited to welcome Masoud to our team at such an important moment for Quanterix,” said Kevin Hrusovsky, Chairman and Chief Executive Officer Quanterix. “We are making important strides in advancing our diagnostic capability and assays, given the NIH RADx funding, our COVID-19 Emergency Use Authorizat...

 PRESS RELEASE
QTRX Quanterix Corpo... (Health Care)

Quanterix Corporation Releases Operating Results for First Quarter 202...

BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ: QTRX), a company helping to transform healthcare with digital protein biomarker technology enabling precision health, today announced financial results for the three months ending March 31, 2021. “We made productive advances on our strategic and operational priorities during the first quarter 2021,” said Chairman, Chief Executive Officer and President, Quanterix, Kevin Hrusovsky. “The precision health ecosystem continues to catalyze interest and adoption from healthcare payors, government agencies, academia, and pharmaceutical companies as they ma...

QTRX Quanterix Corpo... (Health Care)

Quanterix Corp: 1 director

A director at Quanterix Corp sold after exercising options/sold 16,661 shares at 55.469USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listi...

 PRESS RELEASE
QTRX Quanterix Corpo... (Health Care)

Quanterix’ Simoa Technology Powers Largest and Most Diverse Global Inv...

BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its has been used in a worldwide collaborative study of the plasma neurofilament light (NfL) biomarker to evaluate its utility for a range of neurological conditions. Published in , the research marks the most robust effort to date assessing the use of NfL in blood to screen for neurodegeneration as a cause of cognitive symptoms; differentiate among neurodegenerative disorders and distinguish psychiatric disorders; and de...

 PRESS RELEASE
QTRX Quanterix Corpo... (Health Care)

Quanterix Chairman and CEO Kevin Hrusovsky to Present at the Goldman S...

BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that Chairman and Chief Executive Officer, Quanterix, Kevin Hrusovsky will be delivering a virtual presentation at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10th at 3:50pm ET. Attendees can access the public webcast at or by visiting the News & Events page within the Investors section of the Quanterix website at . Replays of the webcast will be available on the Quanterix website for 90 days following the conference. ...

 PRESS RELEASE
QTRX Quanterix Corpo... (Health Care)

Quanterix Appoints Masoud Toloue as President of Quanterix and Diagnos...

BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ: QTRX), a company helping to transform healthcare with digital protein biomarker technology enabling precision health, today announced it has named Masoud Toloue to the position of President of Quanterix and Diagnostics, effective June 9, 2021. “We are excited to welcome Masoud to our team at such an important moment for Quanterix,” said Kevin Hrusovsky, Chairman and Chief Executive Officer Quanterix. “We are making important strides in advancing our diagnostic capability and assays, given the NIH RADx funding, our COVID-19 Emergency Use Authorizat...

 PRESS RELEASE
QTRX Quanterix Corpo... (Health Care)

Quanterix Corporation Releases Operating Results for First Quarter 202...

BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ: QTRX), a company helping to transform healthcare with digital protein biomarker technology enabling precision health, today announced financial results for the three months ending March 31, 2021. “We made productive advances on our strategic and operational priorities during the first quarter 2021,” said Chairman, Chief Executive Officer and President, Quanterix, Kevin Hrusovsky. “The precision health ecosystem continues to catalyze interest and adoption from healthcare payors, government agencies, academia, and pharmaceutical companies as they ma...

QTRX Quanterix Corpo... (Health Care)

Quanterix Corp: 1 director

A director at Quanterix Corp sold after exercising options/sold 16,661 shares at 55.469USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listi...

 PRESS RELEASE
QTRX Quanterix Corpo... (Health Care)

Quanterix’ Simoa Technology Powers Largest and Most Diverse Global Inv...

BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its has been used in a worldwide collaborative study of the plasma neurofilament light (NfL) biomarker to evaluate its utility for a range of neurological conditions. Published in , the research marks the most robust effort to date assessing the use of NfL in blood to screen for neurodegeneration as a cause of cognitive symptoms; differentiate among neurodegenerative disorders and distinguish psychiatric disorders; and de...

 PRESS RELEASE
QTRX Quanterix Corpo... (Health Care)

Quanterix Chairman and CEO Kevin Hrusovsky to Present at the Goldman S...

BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that Chairman and Chief Executive Officer, Quanterix, Kevin Hrusovsky will be delivering a virtual presentation at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10th at 3:50pm ET. Attendees can access the public webcast at or by visiting the News & Events page within the Investors section of the Quanterix website at . Replays of the webcast will be available on the Quanterix website for 90 days following the conference. ...

 PRESS RELEASE
QTRX Quanterix Corpo... (Health Care)

Quanterix Appoints Masoud Toloue as President of Quanterix and Diagnos...

BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ: QTRX), a company helping to transform healthcare with digital protein biomarker technology enabling precision health, today announced it has named Masoud Toloue to the position of President of Quanterix and Diagnostics, effective June 9, 2021. “We are excited to welcome Masoud to our team at such an important moment for Quanterix,” said Kevin Hrusovsky, Chairman and Chief Executive Officer Quanterix. “We are making important strides in advancing our diagnostic capability and assays, given the NIH RADx funding, our COVID-19 Emergency Use Authorizat...

 PRESS RELEASE
QTRX Quanterix Corpo... (Health Care)

Quanterix Corporation Releases Operating Results for First Quarter 202...

BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ: QTRX), a company helping to transform healthcare with digital protein biomarker technology enabling precision health, today announced financial results for the three months ending March 31, 2021. “We made productive advances on our strategic and operational priorities during the first quarter 2021,” said Chairman, Chief Executive Officer and President, Quanterix, Kevin Hrusovsky. “The precision health ecosystem continues to catalyze interest and adoption from healthcare payors, government agencies, academia, and pharmaceutical companies as they ma...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch